MA32049B1 - Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp - Google Patents

Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp

Info

Publication number
MA32049B1
MA32049B1 MA32986A MA32986A MA32049B1 MA 32049 B1 MA32049 B1 MA 32049B1 MA 32986 A MA32986 A MA 32986A MA 32986 A MA32986 A MA 32986A MA 32049 B1 MA32049 B1 MA 32049B1
Authority
MA
Morocco
Prior art keywords
inhibitors
topoisomerase
cancer
treatment
barb
Prior art date
Application number
MA32986A
Other languages
Arabic (ar)
English (en)
Inventor
Valeria S Ossovskaya
Charles Bradley
Barry M Sherman
Original Assignee
Bipar Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc
Publication of MA32049B1 publication Critical patent/MA32049B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Selon un aspect, la présente invention a trait à une composition et à un kit comprenant une combinaison d'inhibiteur de topoïsomérase et d'inhibiteur de parp pour le traitement du cancer. Selon un autre aspect, l'invention a trait à un procédé permettant de traiter le cancer qui comprend l'étape consistant à administrer à un sujet une combinaison d'inhibiteur de topoïsomérase et d'inhibiteur deparp. En particulier, l'invention a trait à des compositions et à des procédés permettant de traiter le cancer chez un sujet en inhibant une poly(adp-ribose) polymérase et une topoïsomérase, tout en fournissant des formulations et des modes d'administration de ces compositions.
MA32986A 2007-12-07 2010-07-05 Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp MA32049B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1236407P 2007-12-07 2007-12-07
PCT/US2008/085756 WO2009073869A1 (fr) 2007-12-07 2008-12-05 Traitement du cancer avec des combinaisons d'inhibiteurs de topoïsomérase et d'inhibiteurs de parp

Publications (1)

Publication Number Publication Date
MA32049B1 true MA32049B1 (fr) 2011-02-01

Family

ID=40718219

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32986A MA32049B1 (fr) 2007-12-07 2010-07-05 Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp

Country Status (13)

Country Link
US (1) US20090149397A1 (fr)
EP (1) EP2224804A4 (fr)
JP (1) JP2011506343A (fr)
KR (1) KR20100102637A (fr)
CN (1) CN101888777A (fr)
AU (1) AU2008333786A1 (fr)
CA (1) CA2708157A1 (fr)
CO (1) CO6321188A2 (fr)
IL (1) IL206209A0 (fr)
MA (1) MA32049B1 (fr)
MX (1) MX2010006154A (fr)
RU (1) RU2010128107A (fr)
WO (1) WO2009073869A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
JP2010504079A (ja) * 2006-06-12 2010-02-12 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤を用いる疾病の治療方法
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030892A2 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Concept de médicament pour inhibiteurs de tubuline, compositions et procédés de traitement
AU2007292387A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
CN102379884A (zh) * 2006-09-05 2012-03-21 彼帕科学公司 Parp抑制剂对脂肪酸合成的抑制及其治疗方法
SG185952A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
US20090123419A1 (en) * 2007-11-12 2009-05-14 Bipar Sciences Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
ES2354922B1 (es) * 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
EP2338486A1 (fr) * 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz Dérivés de 3-(indolyl)- ou de 3-(azaindolyl)-4-arylmaléimide pour usage dans le traitement de l'adenocarcinome du colon et de l'estomac
NZ606725A (en) 2010-08-24 2014-06-27 Dana Farber Cancer Inst Inc Methods for predicting anti-cancer response
RU2565079C2 (ru) 2010-11-05 2015-10-20 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Бензамидные производные, обладающие противораковой активностью, способ их получения и их применение
JP6117194B2 (ja) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド アレル不均衡を評価するための方法および材料
CN104081206B (zh) 2011-07-08 2017-06-09 索隆-基特林癌症研究协会 标记的hsp90抑制剂的用途
EP2745850B1 (fr) * 2011-09-16 2018-05-16 Shimadzu Corporation Nanoparticules pour radiothérapie interne d'une zone concernée et système de thérapie
EP2794907B2 (fr) 2011-12-21 2022-11-23 Myriad Genetics, Inc. Procédés et matériaux pour évaluer la perte d'hétérozygotie
KR20220137154A (ko) 2012-01-20 2022-10-11 데니스 엠. 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
WO2013182645A1 (fr) 2012-06-07 2013-12-12 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014133085A1 (fr) * 2013-02-27 2014-09-04 国立大学法人京都大学 Composition pharmaceutique pour la prévention et/ou le traitement d'un cancer
WO2014160080A1 (fr) 2013-03-14 2014-10-02 Children's Medical Center Corporation Diagnostic du cancer, sélection de traitement et traitement
GB201316526D0 (en) * 2013-09-17 2013-10-30 King S College London Biomarkers
EP3080292B1 (fr) 2013-12-09 2022-02-02 Institut Curie Procédé de détection de l'inactivation de la voie de recombination homologue (brca1/2) dans des tumeurs humaines
US10653689B2 (en) 2014-01-14 2020-05-19 Nektar Therapeutics Combination-based treatment method
PT3180447T (pt) 2014-08-15 2020-06-18 Myriad Genetics Inc Métodos e materiais para avaliar a deficiência de recombinação homóloga
WO2016112177A1 (fr) * 2015-01-08 2016-07-14 Yale University Nouvelles compositions utiles pour tuer des cellules cancéreuses à réparation insuffisante de l'adn, et méthodes d'utilisation de celles-ci
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
ES2826826T3 (es) 2015-08-21 2021-05-19 Ipsen Biopharm Ltd Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
WO2018083470A1 (fr) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
TWI651088B (zh) 2017-03-23 2019-02-21 國立東華大學 用於治療癌症的Scalarane二倍半萜類、醫藥組合物及拓樸異構酶II與 Hsp90抑制劑及其用途與製備方法
WO2018237327A1 (fr) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
US20190110993A1 (en) * 2017-09-12 2019-04-18 Raj Selvaraj Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
WO2019194738A1 (fr) 2018-04-05 2019-10-10 Noviga Research Ab Nouvelles associations d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur de la poly(adp-ribose) polymérase (parp) destinées à être utilisées dans le traitement du cancer
EP3738593A1 (fr) * 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2669583A (en) * 1954-02-16 X-amroo-zralkoxbbenzamdjes
US2006735A (en) * 1932-11-17 1935-07-02 Gen Aniline Works Inc Nitro-aryl amino-aryl amines
LU38172A1 (fr) * 1957-11-25
US3228833A (en) * 1962-12-17 1966-01-11 Sterling Drug Inc Anticoccidial compositions and methods of using same
US5215738A (en) * 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) * 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
DE3750093T2 (de) * 1986-01-17 1995-01-26 Daniel G Miller Test zur Feststellung der Empfänglichkeit für DNS-assoziierte Krankheiten.
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
US5719151A (en) * 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
CZ51593A3 (en) * 1990-09-28 1994-01-19 Smithkline Beecham Corp Water-soluble analogs of camptothecine, process of their preparation and use
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5162532A (en) * 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en) * 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5191082A (en) * 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5464871A (en) * 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6017958A (en) * 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
EP1003498A4 (fr) * 1997-03-26 2004-07-14 Biosource Tech Inc Ethers di-aryle et leurs derives utilises comme agents anticancereux
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6235748B1 (en) * 1997-09-03 2001-05-22 Guilford Pharmaceuticals Inc. Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6380193B1 (en) * 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6387902B1 (en) * 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) * 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
AU2001264595A1 (en) * 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
ITMI20002358A1 (it) * 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2003137064A (ja) * 2001-11-02 2003-05-14 Tokai Rika Co Ltd バックル装置
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
CA2505520C (fr) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
JP2007535895A (ja) * 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
WO2004105700A2 (fr) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Composes, procedes et compositions pharmaceutiques destines a l'inhibition de la parp
US20050004038A1 (en) * 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
MXPA06001110A (es) * 2003-08-01 2006-04-11 Wyeth Corp Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer.
KR20060088102A (ko) * 2003-09-04 2006-08-03 아벤티스 파마슈티칼스 인크. 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ)의 억제제로서의치환된 인돌
WO2005023765A1 (fr) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Methode de catalyse de reactions d'amidation au moyen de co2
US7439031B2 (en) * 2003-12-15 2008-10-21 The Trustees Of The University Of Pennsylvania Method of identifying compounds that induce cell death by necrosis
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
KR100853601B1 (ko) * 2004-09-22 2008-08-22 화이자 인코포레이티드 8-플루오로-2-｛4-[(메틸아미노)메틸]페닐｝-1,3,4,5-테트라하이드로-6Ｈ-아제피노[5,4,3-ｃｄ]인돌-6-온의포스페이트 염의 다형성 및 무정형 형태
NZ553295A (en) * 2004-09-22 2010-04-30 Pfizer Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
EP1812439B2 (fr) * 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
JP2008543786A (ja) * 2005-06-10 2008-12-04 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ調節因子及び癌の治療
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
DE102006037399A1 (de) * 2006-08-10 2008-02-14 Archimica Gmbh Verfahren zur Herstellung von Arylaminen
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030892A2 (fr) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Concept de médicament pour inhibiteurs de tubuline, compositions et procédés de traitement
US20080076778A1 (en) * 2006-09-05 2008-03-27 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
CN102379884A (zh) * 2006-09-05 2012-03-21 彼帕科学公司 Parp抑制剂对脂肪酸合成的抑制及其治疗方法
WO2009051815A1 (fr) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone
US20090123419A1 (en) * 2007-11-12 2009-05-14 Bipar Sciences Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents

Also Published As

Publication number Publication date
MX2010006154A (es) 2010-09-24
CO6321188A2 (es) 2011-09-20
WO2009073869A1 (fr) 2009-06-11
US20090149397A1 (en) 2009-06-11
EP2224804A4 (fr) 2011-06-01
JP2011506343A (ja) 2011-03-03
EP2224804A1 (fr) 2010-09-08
CN101888777A (zh) 2010-11-17
IL206209A0 (en) 2010-12-30
CA2708157A1 (fr) 2009-06-11
AU2008333786A1 (en) 2009-06-11
RU2010128107A (ru) 2012-01-20
KR20100102637A (ko) 2010-09-24

Similar Documents

Publication Publication Date Title
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
WO2008030883A3 (fr) Traitement du cancer
MA31027B1 (fr) INHIBITEURS DE L'ACTIVITE Akt
TW200738263A (en) ANG2 and VEGF inhibitor combinations
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
WO2007011962A3 (fr) Traitement du cancer
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2009114725A3 (fr) Mobilisation de cellules souches hématopoïétiques
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA200900571A1 (ru) Композиции chk1 ингибиторов
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
PL1948155T3 (pl) Kompozycje farmaceutyczne zawierające droksidopę
TW200800989A (en) Pyrrolopyridine kinase inhibiting compounds
EA201100426A1 (ru) Бициклические ингибиторы киназы
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
WO2009151569A3 (fr) Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b
WO2008011071A3 (fr) Interactions des voies de signaux hedgehog et du récepteur x hépatique
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2010093789A8 (fr) Compositions combinatoires et procédés pour le traitement du cancer
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
MX2009002960A (es) Inhibidores de serina hidrolasa.
WO2007098047A3 (fr) Procédé et compositions pour le traitement de la maladie de parkinson
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation